Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Catabasis Pharmaceuticals Inc.

Latest From Catabasis Pharmaceuticals Inc.

Duchenne Development: Data Sharing May Enable Trials To Move Beyond Six-Minute Walk

Repeated trial failures in this rare disease space have given birth to new alliances – one backed by Critical Path and the other by the CureDuchenne advocacy group – that aim to model disease progression much more accurately through data sharing and rigorous analysis.

Clinical Trials Drug Approval Standards

Catabasis Pursues Bifunctional Mutation-Agnostic Approach To DMD

Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified a NF-κB inhibitor – edasalonexent – as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr Jill Milne, co-founder, president and CEO of Catabasis, describes the company’s ambitions to pursue a pivotal Phase III trial this year.

Rare Diseases Neurology

Pipeline Watch: Phase III Progress With Abemaciclib, Esketamine

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Biopharma Quarterly Dealmaking Statistics, Q4 2016

Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Catabasis Pharmaceuticals Inc.
  • Senior Management
  • Jill C Milne, PhD, CEO
    Michael Jirousek, PhD, CSO
    Joanne M Donovan, MD, PhD, CMO
    Angelika Fretzen, PhD, SVP, Product Dev.
    Ted Hibben, CBO
    Andrew Nichols, PhD, CSO
  • Contact Info
  • Catabasis Pharmaceuticals Inc.
    Phone: (617) 349-1971
    One Kendall Sq., Bldg. 1400E, Ste. B142
    Cambridge, MA 02139